Theravance Biopharma, Inc. (TBPH)

Theravance Biopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	65.27	64.38	57.42	51.35	55.31	71.86
Revenue Growth (YoY)	6.11%	12.12%	11.84%	-7.17%	-23.03%	-2.12%
Cost of Revenue	37.25	37.64	40.62	63.39	193.66	260.95
Gross Profit	28.02	26.74	16.8	-12.05	-138.35	-189.1
Selling, General & Admin	70.8	69.17	70.1	67.07	99.3	108.53
Operating Expenses	73.68	69.17	70.45	67.07	99.3	108.53
Operating Income	-45.66	-42.44	-53.65	-79.12	-237.64	-297.63
Interest Expense	-2.56	-2.55	-2.35	-6.37	-8.55	-8.55
Interest & Investment Income	4.98	4.98	9.02	6.74	2.01	4.74
Currency Exchange Gain (Loss)	-0.1	-0.1	0.1	-0.9	-0.9	-0.3
Other Non Operating Income (Expenses)	-0.5	-	-	-	-	-1.61
EBT Excluding Unusual Items	-43.84	-40.1	-46.88	-79.65	-245.08	-303.34
Merger & Restructuring Charges	-	-	-2.39	-12.84	-20.14	-
Gain (Loss) on Sale of Assets	-	-	-	2.71	-	-
Asset Writedown	-4.51	-4.51	-	-	-	-
Other Unusual Items	-	-	-	-3.03	-	-
Pretax Income	-48.35	-44.61	-49.27	-92.82	-265.22	-303.34
Income Tax Expense	9.98	11.8	5.92	0.01	-0.15	-8.52
Earnings From Continuing Operations	-58.33	-56.42	-55.19	-92.82	-265.07	-294.82
Earnings From Discontinued Operations	-	-	-	964.96	65.65	16.81
Net Income	-58.33	-56.42	-55.19	872.13	-199.43	-278.02
Net Income to Common	-58.33	-56.42	-55.19	872.13	-199.43	-278.02
Shares Outstanding (Basic)	49	49	55	74	69	62
Shares Outstanding (Diluted)	49	49	55	74	69	62
Shares Change (YoY)	-4.72%	-11.67%	-24.85%	5.95%	11.41%	12.11%
EPS (Basic)	-1.19	-1.15	-1.00	11.85	-2.87	-4.46
EPS (Diluted)	-1.19	-1.15	-1.00	11.85	-2.87	-4.46
Free Cash Flow	32.29	-11.87	-29.49	-187.56	-211.26	-257.02
Free Cash Flow Per Share	0.66	-0.24	-0.53	-2.55	-3.04	-4.12
Gross Margin	42.93%	41.53%	29.26%	-23.46%	-250.12%	-263.16%
Operating Margin	-69.96%	-65.91%	-93.43%	-154.09%	-429.65%	-414.19%
Profit Margin	-89.38%	-87.63%	-96.11%	1698.54%	-360.55%	-386.90%
Free Cash Flow Margin	49.47%	-18.43%	-51.35%	-365.29%	-381.96%	-357.68%
EBITDA	-43.97	-40.73	-51.65	-76.08	-232.83	-294
EBITDA Margin	-67.37%	-63.26%	-89.94%	-148.18%	-	-
D&A For EBITDA	1.69	1.71	2	3.04	4.81	3.63
EBIT	-45.66	-42.44	-53.65	-79.12	-237.64	-297.63
EBIT Margin	-69.96%	-65.91%	-93.43%	-154.09%	-	-
Revenue as Reported	65.27	64.38	57.42	51.35	55.31	71.86
Advertising Expenses	-	4.3	5.1	8	9.3	6.3

Updated Mar 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q